<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001341</url>
  </required_header>
  <id_info>
    <org_study_id>930210</org_study_id>
    <secondary_id>93-C-0210</secondary_id>
    <nct_id>NCT00001341</nct_id>
  </id_info>
  <brief_title>A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease</brief_title>
  <official_title>A Phase I Trial of ZD1694 (TOMUDEXÂ® (Registered Trademark)), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Thymidylate synthase (TS), an enzyme which acts by utilizing 5,10-CH(2)FH(4) in the reductive&#xD;
      methylation of deoxyuridylate (dUMP), is required for the de novo synthesis of thymidylate&#xD;
      and is a potential chemotherapeutic target. ZD1694 is a new quinazolone folate analog that&#xD;
      directly inhibits TS. This phase I trial and pharmacokinetic study will describe and define&#xD;
      the toxicities, determine the MTD, and describe the plasma pharmacokinetics of ZD1694 in&#xD;
      pediatric patients with refractory cancer. The starting dose for this trial will be 2.0&#xD;
      mg/m(2) administered as a 15 minute IV infusion every 21 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thymidylate synthase (TS), an enzyme which acts by utilizing 5,10-CH(2)FH(4) in the reductive&#xD;
      methylation of deoxyuridylate (dUMP), is required for the de novo synthesis of thymidylate&#xD;
      and is a potential chemotherapeutic target. ZD1694 is a new quinazolone folate analog that&#xD;
      directly inhibits TS. This phase I trial and pharmacokinetic study will describe and define&#xD;
      the toxicities, determine the MTD, and describe the plasma pharmacokinetics of ZD1694 in&#xD;
      pediatric patients with refractory cancer. The starting dose for this trial will be 2.0&#xD;
      mg/m(2) administered as a 15 minute IV infusion every 21 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1993</start_date>
  <completion_date>June 2001</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD1694 (TOMUDEX)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically proven malignancy considered refractory to standard therapy. Objective&#xD;
        evidence of progression on prior therapy required.&#xD;
&#xD;
        No leukemia.&#xD;
&#xD;
        Bone marrow involvement by tumor acceptable. Marrow biopsy required if there is a history&#xD;
        of involvement or peripheral counts are inadequate.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic Therapy: Recovery from toxic effects of prior immunotherapy required.&#xD;
&#xD;
        Chemotherapy: No more than 2 prior chemotherapy regimens and recovered. At least 2 weeks&#xD;
        since myelosuppressive therapy (6 weeks since nitrosoureas).&#xD;
&#xD;
        Endocrine Therapy: Not specified.&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
        No prior central axis irradiation (i.e., skull, spine, ribs, pelvis).&#xD;
&#xD;
        Recovery from toxic effects of prior radiotherapy required.&#xD;
&#xD;
        Surgery: Not specified.&#xD;
&#xD;
        Other: No prior bone marrow transplantation.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 21 and under.&#xD;
&#xD;
        Performance status: ECOG 0-2.&#xD;
&#xD;
        Life expectancy: At least 8 weeks.&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
        (unless histologic evidence of bone marrow involvement by tumor).&#xD;
&#xD;
        AGC at least 1,500/mm3.&#xD;
&#xD;
        Platelet count at least 100,000/mm3.&#xD;
&#xD;
        Hemoglobin at least 8.0 g/dL.&#xD;
&#xD;
        Prior transfusion acceptable.&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
        Bilirubin no greater than 2 times normal.&#xD;
&#xD;
        ALT no greater than 2 times normal.&#xD;
&#xD;
        Renal:&#xD;
&#xD;
        Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
        Creatinine clearance greater than 60 mL/min/1.73 sqm.&#xD;
&#xD;
        Cardiovascular: Not specified.&#xD;
&#xD;
        Pulmonary: Not specified.&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        No significant accumulation of third space fluid.&#xD;
&#xD;
        No significant systemic illness (e.g., infection).&#xD;
&#xD;
        No pregnant or nursing women.&#xD;
&#xD;
        Pregnancy test required in fertile women.&#xD;
&#xD;
        All patients or their guardians must sign an informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 1991 Oct 15;51(20):5579-86.</citation>
    <PMID>1913676</PMID>
  </reference>
  <reference>
    <citation>Jackman AL, Marsham PR, Moran RG, Kimbell R, O'Connor BM, Hughes LR, Calvert AH. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates. Adv Enzyme Regul. 1991;31:13-27. doi: 10.1016/0065-2571(91)90006-8.</citation>
    <PMID>1877386</PMID>
  </reference>
  <reference>
    <citation>Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Eur J Cancer. 1995 Nov;31A(12):1945-54. doi: 10.1016/0959-8049(95)00502-1.</citation>
    <PMID>8562146</PMID>
  </reference>
  <verification_date>August 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Antifolate</keyword>
  <keyword>Inhibitor</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Thymidylate Synthetase</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

